Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today reported financial results for the quarter and fiscal year ended December 31, 2007.

Total revenue for the fourth quarter of 2007 was $2.0 million, with a net loss of $8.8 million. Total revenue for the year ended December 31, 2007 was $9.7 million, with a net loss of $38.8 million. As of December 31, 2007, cash, cash equivalents and marketable securities totaled $47.7 million, and debt totaled $2.3 million. Net cash used in operating activities in 2007 was $34.5 million.

Recent Highlights

-- This week at the 39th Annual Meeting on Women's Cancer hosted by the Society for Gynecologic Oncology in Tampa, Florida, Sunesis presented positive interim results from the company's ongoing Phase 2 clinical trial of SNS-595, a novel naphthyridine analog, in advanced platinum-resistant ovarian cancer patients.
-- Sixty-five women have been enrolled and treated with single-agent

SNS-595 at a dose of 48 mg/m2 administered once every three weeks,

with the majority of these women having been enrolled since October.

Forty-five women have sufficient follow up to yield useful safety

results and 35 are evaluable for best response using GOG-RECIST

criteria.

-- In this trial, SNS-595 has demonstrated disease control (defined as

stable disease, partial response or complete response), with 31 of

35 of evaluable patients having best responses of stable disease or

better. Of
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... (PRWEB) July 24, 2014 Draper ... , is proud to announce that for 6 ... different countries will converge on the Draper University ... an intensive, experiential program focused on entrepreneurship, building ... selective school, currently running its sixth cohort, continues ...
(Date:7/23/2014)... 24, 2014 Lyfebulb, the International Pemphigus ... and NASDAQ OMX First North Premier, ... announced a collaboration to increase awareness of unmet ... an event attended by more than sixty patients, ... a health and wellness company dedicated to serving ...
(Date:7/23/2014)... Helmholtz-Zentrum Dresden-Rossendorf (HZDR), the Vienna University of Technology ... in embedding nearly perfect semiconductor crystals into a ... hybrid nanowires, very fast and multi-functional processing units ... the future. The research results will be published ... Nano-optoelectronics are considered the cornerstone of future chip ...
(Date:7/23/2014)... , July 23, 2014  Having the right ... is vital to accelerating business growth and achieving clinical ... Hospital Association (AHA) Leadership Summit, July 20-22, 2014, in ... panel of hospital executives and healthcare experts discussing how ... Joanne Carrocino , President & Chief Executive Officer of ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5A crystal wedding in the nanocosmos 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2
... chemists at Lehigh University have experimentally verified the "rainbow" ... light waves over a broad range of wavelengths. ... be slowed down or stopped using plasmonic structures has ... The Lehigh experiment employed focused ion beams to mill ...
... Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka ... (EC) has granted marketing authorization for Teysuno™ (S-1), a ... adults with advanced gastric cancer when given in combination ... Member States and the three European Economic Area (EEA) ...
... Co., Inc. (NYSE Amex: TPI ), a ... traditional Chinese medicine, branded generics and other pharmaceuticals is ... Growth Stock Conference from March 13 - 16, 2011 ... Dr. James Jiayuan Tong, Chief Financial Officer, Chief ...
Cached Biology Technology:Trapping a rainbow: Lehigh researchers slow broadband light waves with nanoplasmonic structures 2Teysuno™ (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer 2Teysuno™ (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer 3TPI Attends 23rd ROTH Annual OC Growth Stock Conference from March 13-16, 2011 2
(Date:7/23/2014)... Migratory songbirds are disappearing, and though conservationists are examining ... habitat, acid rain and light pollution, a key piece ... birds go once they leave their breeding sites, and ... , To answer this question, a team of researchers ... migratory connectivity map produced for a songbird, using tracking ...
(Date:7/23/2014)... around the world have no access to clean drinking ... million people die from water-related diseases every year. ETH ... a contribution to solving this problem. Working with researchers ... the Functional Materials Laboratory, the 23-year-old spent a year ... "What makes our DrinkPure filter unique is that you ...
(Date:7/23/2014)... available in German . ... cells, drive metabolic processes and transmit signals. To perform ... Scientists at the Max Planck Institute for Developmental Biology ... constructed of similar amino acid chains even when their ... that exist today arose from common precursors. Presumably, in ...
Breaking Biology News(10 mins):York University researchers use bird 'backpacks' to put wood thrushes migration on the map 2ETH student develops filter for clean water around the world 2Protein evolution follows a modular principle 2
... small nucleus, is the term coined by early biologists ... saw under the microscope. In this structure within the ... ribosomes, the true protein factories of cells. ... diseases, most recently also in neurodegenerative disorders such as ...
... Feb. 1, 2011/PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., ... ("Weikang" or the "Company"), a leading developer, manufacturer ... prescription and OTC pharmaceuticals and other health and ... today announced the completion of its private placement ...
... future diagnosis and treatment of lupus, an immune ... researchers at the Virginia-Maryland Regional College of Veterinary ... the breakdown in the body,s lymphocyte molecular regulatory ... and her colleagues in the veterinary college,s Department ...
Cached Biology News:A possible cause of Parkinson's disease discovered 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 3Research uncovers key to understanding cause of lupus 2
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
... imaging system for detection of very low ... size. Equipped with an extreme sensitive camera ... or plants in tumor research, infectious disease ... blots. NightOWL is the only imager with ...
... cell sorter sets a new standard for ... a revolutionary new design in instrumentation, this ... multicolor analysis. The BD FACSAria instrument is ... fixed-alignment cuvette flow cell. This new ...
Biology Products: